Business
NeoGenomics Announces Leadership Appointments
FT. MYERS, FL / ACCESSWIRE / February 5, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today

About this update from Neogenomics, Inc.
[{"type":"text","content":"FT. MYERS, FL / ACCESSWIRE / February 5, 2020 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services, announced today three important leadership appointments.Kathryn McKenzie is named Chief Financial Officer. Ms. McKenzie joined NeoGenomics in 2017 and has recently served as our Vice President of Finance and Chief Accounting Officer. For the past six months, Kathryn has assumed a key finance leadership role at our company. Before joining NeoGenomics, Ms. McKenzie served in various roles at Chico's FAS, including Assistant Controller and Director of Financial Reporting and Treasury, and at Ernst and Young. Ms. McKenzie is a Certified Public Accountant and holds a Master's of Science in Accountancy from the University of North Carolina Wilmington.William Bonello will become President, Informatics Division. Mr. Bonello most recently served as our Chief Strategy and Corporate Development Officer helping to formulate the company's growth strategy. Bill will continue to serve as Director of Investor Relations, a position he has held since 2018. Prior to joining NeoGenomics, Bill worked as a healthcare equity analyst covering diagnostic services and product stocks at Craig-Hallum and at a variety of firms, and was also Senior Vice President for Investor Relations at LabCorp. Mr. Bonello received his B.A. degree from Carleton College and his MBA from the Kellogg School of Management at Northwestern University.Douglas Brown is joining NeoGenomics as Chief Strategy and Corporate Development Officer. Prior to joining NeoGenomics, Mr. Brown was Senior Managing Director with SVB Leerink with significant expertise in the oncology diagnostic sector. During his career, he has advised clients in over 100 successful M&A and Corporate Financing transactions. Doug advised General Electric on the sale of Clarient, and recently advised NeoGenomics on the acquisition of Genoptix and the oncology assets of Human Longevity. Mr. Brown earned his MBA from the Fuqua School of Business at Duke University and received his undergraduate business degree from the University of Texas at Austin.\"Our Board of Directors and Management Team are very excited to have such a talented executive as Kathryn McKenzie become our Chief Financial Officer, to have such an outstanding and experienced executive as Doug Brown join our lea...